STARPHARMA HOLDINGS

SPL
Delayed Quote. Delayed  - 01/25 12:10:15 am
1.035AUD -2.36%

Starpharma Holdings Limited Announces Positive Interim Results from Its Ongoing Phase 2 Trial of DEP? Cabazitaxel

11/24/2021 | 07:04pm
Starpharma Holdings Limited announced positive interim results from its ongoing phase 2 trial of DEP? cabazitaxel, showing that 100% (22/22) of evaluable 3 patients with hormone refractory, (Stage IV) metastatic prostate cancer. All of these patients have been heavily pre-treated and have had efficacy responses, utilising one or more standard measures of disease. These interim results in prostate cancer show that one or more encouraging efficacy signals were observed in 100% of patients assessed following DEP? cabazitaxel treatment, and 56% of patients who were evaluable for all three efficacy measures had responses to all three measures. Responses included: 64% of patients with assessable tumour lesions saw prolonged stable disease and significant reductions in tumour size for up to 36 weeks with some patients still receiving treatment; 90% of patients with assessable PSA (Prostate Specific Antigen) tumour biomarker levels had a reduction in PSA, with more than half of these patients achieving a reduction in PSA of at least 50%; 83% of patients with secondary bone disease exhibited either no progression or an improvement in these lesions.
© S&P Capital IQ 2022
Copier lien
All news about STARPHARMA HOLDINGS LIMITED
3d ago
5d ago
12/15
12/14
12/13